Life Sciences Outlook 2012 Dutch biotech companies ... - NautaDutilh

Table of
contents.
Preface 3
Introduction 6
Key developments in the life sciences world 6
The general economic climate 7
1. Start-up 9
Academic institutes as the Petri dish
for biotech companies 10
Too small, too early? More structure
needed for spin-offs? 11
Matching the guy in the lab with the suits
and ties 14
Funding it all: seed capital 15
The role of government 16
2. Investing 19
Separating the wheat from the chaff 19
The big squeeze 20
Big Pharma steps in 21
Weeding out the nonsense 22
The view from the receiving end 24
Towards a symbiotic relationship 24
3. Strategic co-operation 27
Sharing a future together 27
A lack of ambition or healthy realism? 28
Exceptions 29
How to manage the relationship between
biotech and Big Pharma 29
Implications 30
4. Exit strategy 33
Sale to Big Pharma as a much preferred
exit route 34
The end of the line for management 35
“An IPO? Can’t get it done!” 35
But what if? 38
Conclusions 40
Methodology 42
About NautaDutilh 44
About Niaba 45
Key contacts 46
Disclaimer 51
Room for notes 52
Life Sciences Outlook 2012 Dutch biotech companies: from start-up to exit
5